{"id":"W2028031291","doi":"10.1056/nejmoa0707330","title":"VEGF Inhibition and Renal Thrombotic Microangiopathy","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":1494,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; Heart and Stroke Foundation; University of Toronto; Toronto General Hospital; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Thrombotic microangiopathy; Medicine; Bevacizumab; Microangiopathy; Pathogenesis; Vascular endothelial growth factor; Kidney disease; Kidney; Acute kidney injury; Internal medicine; Pathology; VEGF receptors; Endocrinology; Disease; Chemotherapy; Diabetes mellitus","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01891218373662401,"score_gpt":0.2556618291109133,"score_spread":0.2367496453742893,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}